A Randomized, Double-Blind, Placebo Controlled Dose Titration Trial With 0.125-0.75mg Pramipexole (Sifrol) Orally q.n. to Investigate the Safety and Efficacy in Out-Patients With Idiopathic Restless Legs Syndrome for 6 Weeks.

Trial Profile

A Randomized, Double-Blind, Placebo Controlled Dose Titration Trial With 0.125-0.75mg Pramipexole (Sifrol) Orally q.n. to Investigate the Safety and Efficacy in Out-Patients With Idiopathic Restless Legs Syndrome for 6 Weeks.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Restless legs syndrome
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 09 Mar 2010 Patient numbers amended from (305) to (306) as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Actual patient number (305) added as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top